MX2012007229A - Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos. - Google Patents

Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos.

Info

Publication number
MX2012007229A
MX2012007229A MX2012007229A MX2012007229A MX2012007229A MX 2012007229 A MX2012007229 A MX 2012007229A MX 2012007229 A MX2012007229 A MX 2012007229A MX 2012007229 A MX2012007229 A MX 2012007229A MX 2012007229 A MX2012007229 A MX 2012007229A
Authority
MX
Mexico
Prior art keywords
analogue
vitamin
solvent
mixture
surfactants
Prior art date
Application number
MX2012007229A
Other languages
English (en)
Spanish (es)
Inventor
Karsten Petersson
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2012007229A publication Critical patent/MX2012007229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
MX2012007229A 2009-12-22 2010-12-22 Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos. MX2012007229A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK2009000265 2009-12-22
US29310510P 2010-01-07 2010-01-07
PCT/DK2010/000182 WO2011076207A2 (en) 2009-12-22 2010-12-22 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants

Publications (1)

Publication Number Publication Date
MX2012007229A true MX2012007229A (es) 2012-07-30

Family

ID=43618132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007229A MX2012007229A (es) 2009-12-22 2010-12-22 Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos.

Country Status (13)

Country Link
US (2) US20120322776A1 (cg-RX-API-DMAC7.html)
EP (1) EP2515865B1 (cg-RX-API-DMAC7.html)
JP (1) JP5873439B2 (cg-RX-API-DMAC7.html)
CN (1) CN102781425B (cg-RX-API-DMAC7.html)
AU (1) AU2010335654B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012015433B8 (cg-RX-API-DMAC7.html)
CA (1) CA2785251A1 (cg-RX-API-DMAC7.html)
IL (1) IL220514A (cg-RX-API-DMAC7.html)
MX (1) MX2012007229A (cg-RX-API-DMAC7.html)
NZ (1) NZ600999A (cg-RX-API-DMAC7.html)
RU (1) RU2560677C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011076207A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204620B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5570442B2 (ja) * 2011-01-24 2014-08-13 株式会社シャネル化粧品技術開発研究所 水中油型乳化組成物及びその製造方法
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
US9638703B2 (en) * 2013-12-19 2017-05-02 Universiteit Gent Quantification of glucocorticoids in fish scales as biomarkers for chronic stress
CN104666312B (zh) * 2015-02-12 2017-11-07 重庆华邦制药有限公司 含有卡泊三醇和二丙酸倍他米松的制剂
CN106265485A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种稳定性改善的卡泊三醇组合物
CN106265511A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种性能优异的卡泊三醇倍他米松自微乳制剂
CN106442841B (zh) * 2016-12-16 2018-09-14 上海景峰制药有限公司 一种药物中阳离子表面活性剂的分离检测方法
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
KR102678365B1 (ko) * 2018-03-20 2024-06-26 재단법인 경기도경제과학진흥원 콜레칼시페롤의 가용화 조성물 및 그 제조방법
EP3741378A1 (de) 2019-05-23 2020-11-25 Dimitrios Tsakouridis Zusammensetzung zur topischen behandlung und pflege der psoriatischen haut
CA3091554A1 (en) * 2020-08-28 2022-02-28 Triple Hair Inc. Formulations for reducing hair loss and/or increasing hair regrowth
JP2024163642A (ja) * 2023-05-12 2024-11-22 アピ株式会社 外用組成物
JP7633712B2 (ja) * 2023-05-12 2025-02-20 アピ株式会社 外用組成物
CN118304279B (zh) * 2024-03-27 2025-04-25 青岛双鲸药业股份有限公司 一种骨化三醇自微乳口溶膜及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753377B1 (fr) * 1996-09-19 1999-09-24 Rhone Merieux Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JP2655190B2 (ja) * 1989-06-21 1997-09-17 エスエス製薬 株式会社 コルチコステロイド含有軟膏剤
NZ243703A (en) * 1991-07-26 1995-12-21 Smithkline Beecham Corp Pharmaceutically acceptable, stable, self-emulsifying w/o microemulsions containing a water-soluble therapeutic agent, microemulsions
US5766628A (en) * 1992-02-24 1998-06-16 Merz + Co. Gmbh & Co. Bath and shower composition having vesicle-forming properties and method for the production and use thereof
USRE39706E1 (en) 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
EP0753311B1 (en) 1993-04-19 2002-09-04 Institute For Advanced Skin Research Inc. Microemulsion preparation containing a substance which is difficult to be absorbed
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9602111D0 (en) * 1996-02-02 1996-04-03 Unilever Plc Personal care composition
GB9611603D0 (en) * 1996-06-04 1996-08-07 Leo Pharm Prod Ltd Chemical compounds
US6432422B1 (en) * 1997-12-09 2002-08-13 Chugai Seiyaku Kabushiki Kaisha Creams containing vitamin D3 derivatives
US5989531A (en) * 1998-11-13 1999-11-23 Colgate-Palmolive Company Antiperspirant formulation for porous applicator
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6582683B2 (en) * 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
WO2006120681A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
IL154888A0 (en) * 2000-10-27 2003-10-31 Leo Pharma As Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
US7005557B2 (en) * 2001-07-03 2006-02-28 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
EP1643967A1 (en) * 2003-06-17 2006-04-12 E.I. Dupont De Nemours And Company Modified soy proteins in personal care compositions
DE602004027504D1 (de) 2003-07-24 2010-07-15 Leo Pharma As Aminobenzophenonverbindungen
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
CA2567683A1 (en) * 2004-06-17 2005-12-29 Galderma S.A. Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase
CA2590479A1 (en) 2004-12-13 2006-06-22 Leo Pharma A/S Triazole substituted aminobenzophenone compounds
MX2007007747A (es) * 2004-12-23 2007-08-14 Unilever Nv Emulsiones agua-en-aceite para tratamiento de cabello.
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis
FR2887150B1 (fr) * 2005-06-17 2007-08-03 Galderma Res & Dev Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
US20070249055A1 (en) * 2006-04-24 2007-10-25 The Procter & Gamble Company Method of measuring lotion and additive ingredient transfer
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
US8148537B2 (en) 2006-12-22 2012-04-03 Leo Pharma A/S Substituted acetophenones useful as PDE4 inhibitors
MY150075A (en) 2007-02-28 2013-11-29 Leo Pharma As Novel phosphodiesterase inhibitors
EP1970049A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D and corticosteroid
EP2146703A1 (en) 2007-04-19 2010-01-27 Leo Pharma A/S Src family kinase inhibitors
WO2008134512A1 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
EP2146780A1 (en) 2007-05-11 2010-01-27 Sonneborn Inc. Petrolatums having silicone-like properties
US20080299156A1 (en) * 2007-06-01 2008-12-04 L'oreal Skin care compositions containing a high internal phase emulsion
HRP20160488T1 (hr) 2008-12-19 2016-06-17 Leo Pharma A/S Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti
WO2011000765A1 (en) * 2009-06-29 2011-01-06 Glaxo Group Limited New medical use

Also Published As

Publication number Publication date
CA2785251A1 (en) 2011-06-30
JP2013515018A (ja) 2013-05-02
CN102781425A (zh) 2012-11-14
WO2011076207A3 (en) 2012-03-01
RU2560677C2 (ru) 2015-08-20
WO2011076207A2 (en) 2011-06-30
NZ600999A (en) 2014-06-27
AU2010335654B2 (en) 2015-04-09
CN102781425B (zh) 2014-08-13
US20120322776A1 (en) 2012-12-20
US20160324875A1 (en) 2016-11-10
AU2010335654A1 (en) 2012-07-26
RU2012130421A (ru) 2014-01-27
HK1177899A1 (en) 2013-08-30
JP5873439B2 (ja) 2016-03-01
IL220514A (en) 2017-01-31
BR112012015433B1 (pt) 2019-04-24
ZA201204620B (en) 2013-09-25
EP2515865B1 (en) 2016-12-14
BR112012015433A2 (pt) 2016-03-15
EP2515865A2 (en) 2012-10-31
BR112012015433B8 (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
MX2012007229A (es) Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
TNSN08381A1 (en) Cosmetic active ingredient composed of arginine ferrulate and a microalgae and extract its uses
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
IL190838A0 (en) Intranasal administration of rapid acting insulin
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
CR20120605A (es) Formulación tópica para un inhibidor de jak
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
SG162798A1 (en) Liquid pharmaceutical formulations of docetaxel
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
ECSP11011459A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EP2515912A4 (en) PHARMACEUTICAL COMPOSITION WITH VITAMIN D ANALOGON AND COLOSTERS-TENSID MIXTURE
WO2012130820A3 (de) Isopentylester zur verwendung in kosmetischen, dermatologischen oder pharmazeutischen kompositionen
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
GT200800117A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y uso
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
EP2361083A4 (en) COMPOSITION FOR THE TREATMENT OF EPITHELIAL TISSUE
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
WO2014106826A3 (en) Anthracycline analogue and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration